Hyderabad Pharma City at Mucherla and Kandukur

Government of Telangana State proposes to develop HYDERABAD PHARMA CITY at Mucherla and Kandukur near Hyderabad. 

Why in Hyderabad?

Hyderabad, the “Bulk Drug Capital of India”, accounts for 30% of pharma exports from India, while Telangana State contributes to 1/3rd of the total pharma production in the country. There are around 400 plus pharma companies including 170 plus bulk drug units in Telangana. Hyderabad also has witnessed infrastructural development in the biotech domain wherein the Knowledge Park, the Biotech Park, Genome Valley and other projects have come up giving the city an advantage over others.

Hyderabad is also a hub for R&D Centres like Centre for Cellular and Molecular Biology (CCMB), Indian Institute of Chemical Technology (IICT), International Crop Research Institute for Semi-arid Tropics
(ICRISAT), Central Food Technology Research Institute (CFTRI) and Institute for Life Sciences Centre (ILSC).



at Kandukur on Srishailam Highway. Cont: 81257 55666


 The HYDERABAD PHARMA CITY is proposed to be developed with integrated physical, environmental, social and technical infrastructure in an area of 19,333.20 acres   (78.24 sq.km) of land in Ranga Reddy District of Telangana State.

The following figure shows the key map of the Project Site location.

(Map showing general location, specific location, and project boundary & project site Layout with Coordinates)

Key components of the Hyderabad Pharma City Project include:

(A) Pharma NIMZ   (for pharma manufacturing and allied activities)

(B) Pharma City Township (for housing and allied social infrastructure)

(C) Pharma University (exclusive university for pharmaceutical sector)

(D) Pharma R&D and Ancillary Hub (Research & Development Hub; hub for ancillary units)

Project Cost Estimate

The total project cost estimate is Rs. 16,395 Crores2 with the following break up:

  •   Land acquisition cost – Rs. 1,550 Crores
  •   Block cost estimate for external linkages – Rs. 6,145 Crores
  •   Block cost estimate for internal site development – Rs. 8,700 Crores

 Socio Economic Benefits of Project

The estimated employment generation potential of the project is 4.25 lakhs including direct employment generation of 1.7 lakhs.

The estimated total investment in pharma manufacturing in the Pharma City by the ultimate phase of project development is Rs. 64,000 Crores, with an estimated turnover of Rs. 1.4 lakh Crores and estimated pharma exports of Rs. 58,000 Crores.

The other project benefits include relocation of pharma units within Hyderabad urban sprawl to an integrated township that is economically, socially and environmentally sustainable. The project will promote domestic API manufacturing that would help reduce the current scenario of huge dependence on API imports which are fraught with risks for the nation. The project is planned in tandem with the Make in India program of the Government of India.



at Kandukur on Srishailam Highway. Cont: 81257 55666



Nature of the Project

Govt of Telangana State has set out a comprehensive vision for Pharma City encompassing the complete range of activities associated with the pharma industry broadly grouped under ‘make’, ‘live’, ‘learn’, ‘innovate’ and ‘excel’. 

MAKE: The Hyderabad Pharma NIMZ, which constitutes pharma manufacturing & related activities, occupies the largest chunk of Pharma City. It shall be developed with all integrated physical, environmental management, technical, and social infrastructure.

EXCEL: Hyderabad Pharma City shall have the necessary supporting trade promotion infrastructure to ensure that its units excel in the trade.

LIVE: Pharma City shall have an exclusive Township with housing facilities for all employee categories, as well as allied social infrastructure covering health, education, entertainment and recreation.

LEARN: Pharma City shall also have a Pharma University that shall provide a steady stream of skilled manpower to the Pharma City. It shall also have a Skill Development Hub for training the manpower to suit the industry requirements.

INNOVATE: Pharma City shall have a Research & Development (R&D) Hub that develops new drugs not only for diseases that are prevalent globally but also for diseases that are specific to India and other tropical countries.


The total industrial plot area demand as per the BDMA list is around 4,000 acres, almost half of which are from 12 units whose demand lies in the 100 acres plus plot categories. These 12 units with the largest plot size demands are:

 Aurobindo Pharma Ltd – 250 acres

 Balaji Amines Ltd – 100 acres

 Dr Reddy’s Laboratories Ltd – 200 acres

 Gland Chemicals Pvt Ltd – 100 acres

 Gland Pharma Ltd – 100 acres

 Granules India Ltd – 100 acres

 Hetero Group – 250 acres

 MSN Laboratories Pvt Ltd – 250 acres

 MSN Pharmachem Pvt Ltd – 150 acres

 Mylan Laboratories Ltd – 100 acres

 Srini Pharmaceuticals Ltd – 100 acres

 Virchow Laboratories Ltd – 200 acres

Apart from BDMA’s land demand, the Telangana Association of Pharma and Chemical Industries (TAPCI) has also indicated to TSIIC, requirement for around 2,000 acres of industrial plots land from its members, largely belonging to the SME category.

Thus there is an immediate pharma industrial land demand for over 6,000 acres while considering promoters from outside the state, multinational companies and manufacturers of API Intermediates the total demand for industrial plotted land in the Hyderabad Pharma City may go up to over 8,000 acres.



at Kandukur on Srishailam Highway. Cont: 81257 55666



10,970 total views, 9 views today